TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

Mobile site search icon.
Mobile navigation icon.

TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

REIMAGINE the way you treat HAE

TAKHZYRO (lanadelumab-flyo) is clinically proven to reduce attacks with the possibility of zero attacks for periods of time -- the only every-2-weeks hereditary angioedema (HAE) treatment evaluated in a 2.5 year study.1-5

About TAKHZYRO SEE IMPORTANT SAFETY INFORMATION

Rediscover Prevention

The safety and efficacy of TAKHZYRO (lanadelumab-flyo) were assessed in a 26-week pivotal trial of 125 HAE patients ≥12 years of age. The primary efficacy endpoint was the rate of investigator-confirmed attacks during the treatment period compared to placebo.1,6

Significant reduction in mean attack rate* vs placebo at 6.5 months (26 weeks)1,6

In the Pivotal Trial

Down arrow icon.
87%

REDUCTION
IN ATTACKS

Vs Placebo
(Adjusted P<0.001)1†

  • TAKHZYRO (lanadelumab-flyo) every 4 weeks resulted in a 73% reduction in attacks vs placebo (Adjusted P<0.001)1†
  • Mean monthly attack rate at baseline (during run-in period): 3.52 for TAKHZYRO every 2 weeks (n=27); 3.71 for TAKHZYRO every 4 weeks (n=29); 4.02 for placebo (n=41)6
  • Mean monthly attack rate (during treatment): 0.26 for TAKHZYRO every 2 weeks; 0.53 for TAKHZYRO every 4 weeks; 1.97 for placebo1

All data presented are for TAKHZYRO 300 mg every 2 weeks unless otherwise indicated.

The pivotal trial was a multicenter, double-blind, parallel-group, placebo controlled, dose-ranging study which assessed the safety and efficacy of TAKHZYRO in 125 patients with HAE type I or II (≥12 years of age). Patients were randomized to receive TAKHZYRO 150 mg every 4 weeks (n=28), TAKHZYRO 300 mg every 4 weeks (n=29), TAKHZYRO 300 mg every 2 weeks (n=27), or placebo (n=41) for 26 weeks (6.5 months, where 1 month was defined as 28 days). Prior to randomization, patients ≥18 years of age were required to complete a ≥2-week long-term prophylaxis washout period. All patients then entered a 4-week run-in period to determine the baseline HAE attack rate. All patients with ≥1 investigator-confirmed HAE attack during the run-in period were eligible for study enrollment and randomization. The primary efficacy endpoint was the rate of investigator-confirmed attacks during the treatment period (time frame: from Day 0 to Day 182) (Adjusted P<0.001 vs placebo for all; adjusted P values for multiple testing).1,6

*Mean monthly attack rate: number of attacks/4 weeks.

Adjusted P values for multiple testing.

Discover our latest published 30-month open-label extension data.2

Review Data

Calendar icon. TAKHZYRO® injection is taken every two weeks.

Rethink dosing and administration

Just 1 subcutaneous self-injection every 2 weeks, requiring no reconstitution.1

The recommended starting dose is 300 mg every 2 weeks. TAKHZYRO every 4 weeks is also effective and may be considered if the patient is well-controlled (eg, attack free) for more than 6 months.1

Review dosing and administration

Visual representation of TAKHZYRO®, a monoclonal antibody.

Refine the approach

The first and only monoclonal antibody (mAb) for HAE, TAKHZYRO inhibits plasma kallikrein activity, a critical regulator of bradykinin production, to help prevent HAE attacks. TAKHZYRO is non-plasma derived.1,3-5

See how TAKHZYRO works

Icon of pen.

TAKHZYRO
Quick Start Program

Get patients started on TAKHZYRO

Get patients started on TAKHZYRO

Takeda will provide eligible patients with immediate access to TAKHZYRO at no cost during potential delays in commercial insurance coverage determinations. Once enrolled, patients will receive assistance from OnePath®, a product support program.

Start your patients right away

Timing is dependent upon when the forms are received by OnePath®. The Quick Start Program is available to all commercially insured patients ≥12 years of age who are US residents with a confirmed diagnosis of HAE. Takeda and its affiliates reserve the right to change or discontinue this program at any time, without notice. Void where prohibited by law. This program does not constitute a financial assistance program.

References: 1. TAKHZYRO (lanadelumab-flyo) [prescribing information]. Lexington, MA: Dyax Corp 2018. 2. Banerji A, Bernstein JA, Johnston DT, et al. Long-term prevention of hereditary angioedema attacks with lanadelumab: the HELP OLE Study. Allergy. Published online July 21, 2021. doi:10.1111/all.15011 3. CINRYZE (C1 esterase inhibitor [human]) [prescribing information]. Lexington, MA: Shire ViroPharma Incorporated; 2021. 4. HAEGARDA [prescribing information]. Kankakee, IL: CSL Behring LLC; 2020. 5. Orladeyo. Prescribing information. BioCryst Pharmaceuticals, Inc; 2020. 6. Banerji A, Riedl MA, Bernstein JA, et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA. 2018;320(20):2108-2121. doi:1001/jama.2018.16773